Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the long-term safety of pirtobrutinib in people who have previously been treated for chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This study welcomes participants who completed the earlier LOXO-BTK-20020 trial to continue receiving the study drug or attend follow-up visits. The study is a Phase 4 treatment trial sponsored by Eli Lilly and Company. Participants will receive pirtobrutinib orally every 4 weeks. There is also a group receiving idelalisib orally. This study is designed as a parallel, non-randomized trial and is expected to last approximately 5 years, allowing continued access to treatment or follow-up for participants from the previous study. During the study, participants will be monitored for treatment-emergent adverse events of grade 3 or higher from the first dose through 30 days after the last dose or start of new anticancer therapy. Researchers will also track overall survival from enrollment in the original study until death from any cause, up to about 93 months. Participants will have regular visits over the study period for safety and health assessments.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System in people with coronary artery disease who have atherosclerotic lesions longer than 36 mm and up to 44 mm in their native coronary arteries. The study focuses on lesions with a reference vessel diameter between 2.25 mm and 4.0 mm. This is a prospective, multicenter, single-arm study sponsored by Teleflex, aiming to treat subjects with these specific lesions using this device. Participants will receive the Orsiro Mission stent, which consists of a cobalt chromium stent platform coated with a bioabsorbable polymer containing the drug sirolimus. This device is designed to be implanted in the coronary arteries during percutaneous coronary intervention PCI. The study involves a single group receiving this stent to assess its performance in treating lesions of the specified length and size. During the study, participants will have follow-up visits to monitor outcomes and safety. Those enrolled in the United States will be followed for 2 years with visits at 1, 6, 12 months, and 2 years after the procedure. Participants outside the United States will be followed for 5 years with additional visits at 3 and 5 years. Researchers will measure target lesion failure at 12 months as the primary outcome and will also track device and procedure success, deaths, heart attacks, major cardiac events, revascularizations, and stent thrombosis throughout the follow-up period.
Actively Recruiting
Researchers are evaluating the clinical outcomes of two medical devices, the Virtue Sirolimus AngioInfusion Balloon SAB and the AGENT Paclitaxel Drug-Coated Balloon DCB, in treating coronary artery in-stent restenosis ISR. This study is a prospective, multi-center, single-blind, randomized trial designed to determine whether the Virtue SAB is not inferior to the AGENT DCB for this condition. Participants will be randomly assigned to receive either the Virtue SAB or the AGENT DCB as part of a percutaneous coronary intervention procedure. Both devices are used to treat ISR, with the Virtue SAB delivering sirolimus and the AGENT DCB delivering paclitaxel. The study compares these two treatments directly, with each balloon covering the affected lesion completely during the angioplasty procedure. During the study, participants will be monitored for up to 12 months, with the primary outcome being Target Lesion Failure TLF measured at 12 months post-treatment. Follow-up visits will include clinical assessments to evaluate the success of the treatment and monitor for any complications. The study aims to collect detailed clinical data over this period to assess the safety and performance of both devices in treating coronary artery ISR.